Sort
39,280 grants matching “leukemia”
Metabolic regulation of hematopoietic stem cell specification and function
$378,450Trista E. North · Beth Israel Deaconess Medical Center · R01 · FY2016 · DK
Metabolic regulation of hematopoietic stem cell specification and function
$378,450Trista E. North · Beth Israel Deaconess Medical Center · R01 · FY2015 · DK
Metabolic regulation of hematopoietic stem cell specification and function
$378,450Trista E. North · Beth Israel Deaconess Medical Center · R01 · FY2014 · DK
Metabolic regulation of hematopoietic stem cell specification and function
$378,450Trista E. North · Beth Israel Deaconess Medical Center · R01 · FY2017 · DK
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
$378,438Jonathan F Lovell · State University Of New York At Buffalo · R01 · FY2021 · CA
Characterization of NUP205 as a haploinsufficient essential gene for the treatment of hematopoietic malignancies
$378,405Haijiao Zhang · Oregon Health & Science University · R37 · FY2024 · CA
Targeting multiple signaling steps to achieve synergy
$378,396M Guillaume Wientjes · Optimum Therapeutics, Llc · R01 · FY2015 · CA
Inactivating EVI1 for the Treatment of Myelodysplastic *
$378,394Giuseppina Nucifora · University Of Illinois At Chicago · R01 · FY2006 · HL
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
$378,389Mark S Berger · Actinium Pharmaceuticals, Inc. · R42 · FY2020 · CA
ELUCIDATION & MODULATION OF NATURAL KILLER CELL SIGNALING: APPLICATION IN CANCER
$378,367Michael A Caligiuri · Ohio State University · P01 · FY2007 · CA
GM-CSF secreting tumor cell vaccines to enhance post-transplant anti-CLL immunity
$378,360Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R21 · FY2008 · CA
GM-CSF secreting tumor cell vaccines to enhance post-transplant anti-CLL immunity
$378,360Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R21 · FY2009 · CA
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors
$378,348Everett Stone · University Of Texas At Austin · R01 · FY2021 · CA
Hoxa9, Meis1, and Pbx in Self-renewal and Leukemogenesis
$378,345Mark P Kamps · University Of California, San Diego · R01 · FY2009 · CA
MicroRNAs' Role in Hematopoietic Lineage Differentiation
$378,345Chang-Zheng Chen · Stanford University · R01 · FY2007 · HL
Human Platelet Defects in Transcription Factor RUNX1 Haplodeficiency
$378,317A Koneti Rao · Temple Univ Of The Commonwealth · R01 · FY2015 · HL
ARP--GENE TARGET OF THE ALL1 GENE IN ACUTE LEUKEMIAS
$378,283Thomas Jefferson University · R01 · FY2002 · CA
Determining how aging-associated changes in the microenvironment contribute to leukemogenesis
$378,263James V Degregori · University Of Colorado Denver · R01 · FY2020 · AG
Molecular Regulation of Mammalian Erythro-Megakaryocytic Development
$378,250Shireen Saleque · City College Of New York · SC1 · FY2017 · HL
Off-the-shelf iPSC-Derived Natural Killer Cell Immunotherapies for AML
$378,249Jeffrey S Miller · University Of Minnesota · P01 · FY2024 · CA
USP18 in Cancer Development
$378,186Dong-Er Zhang · University Of California, San Diego · R01 · FY2021 · CA
Targeting the MLL complex in Castration Resistant Prostate Cancer
$378,124Jolanta Grembecka · University Of Michigan At Ann Arbor · R01 · FY2018 · CA
Targeting to Epigenetic Modications in ALL
$378,115Scott A Armstrong · Sloan-Kettering Inst Can Research · R01 · FY2013 · CA
Glial Cell Inflammatory Mechanisms and CNS Regulation
$378,094Johns Hopkins University · R01 · FY2004 · NS
Glial Cell Inflammatory Mechanisms &CNS Regulation
$378,094Johns Hopkins University · R01 · FY2005 · NS